The Effects of Nano-curcumin Supplementation on Adipokines Levels in Obese and Overweight Patients With Migraine: a Double Blind Clinical Trial Study

Objective: The present study aimed to investigate the effects of nano-curcumin supplementation on adipokines levels and clinical signs in obese and overweight patients with migraine. Results: : Forty-four patients with episodic migraine participated in this clinical trial and were divided into two groups as nano-curcumin (80 mg/day) and control group over a two-month period. At the baseline and the end of the research, the serum levels of MCP-1, Resistin and Visfatine were measured using ELISA method. In addition, the headache attack frequencies, severity and duration of pain were recorded. The results of the present study showed that nano-curcumin can significantly reduce MCP-1 serum levels in nano-curcumin supplemented group (P=0.015, size effect= 13.4%). In the case of resistin and visfatine, a greater reduction was found in nano-curcumin group but it was not statistically significant (P>0.05). Nano-curcumin also significantly reduced the attack frequencies, severity and duration of headaches (P<0.05). These findings indicate that targeting curcumin can be a promising approach to migraine management. However, further comprehensive human trials are needed to confirm these finding. Trial Registration: This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: IRCT20160626028637N2.